Phio Pharmaceuticals Announces Positive Recommendation From Safety Monitoring Committee of Phase 1B Clinical Study of Phio S Lead Compound Ph-762
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.